Fresenius

(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release →

(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release →

(IN BRIEF) Fresenius Kabi’s Santiago de Besteiros plant in Portugal has secured BSI Kitemark™ Certification for Minimized Risk of AMR in its Ceftriaxone production, confirming compliance with the AMR Industry Alliance’s Antibiotic Manufacturing Standard. Key measures include stringent controls to … Read the full press release →

(IN BRIEF) Fresenius Medical Care has received FDA 510(k) clearance for its updated 5008X CAREsystem with additional features, enabling the introduction of high-volume hemodiafiltration therapy across the U.S. This new therapy, proven to reduce mortality rates by 23% in patients, … Read the full press release →

(IN BRIEF) Fresenius Medical Care will showcase a variety of new research at the 62nd Congress of the European Renal Association (ERA) in Vienna, focusing on advancements in kidney care, artificial intelligence, fluid management, and hemodiafiltration. Key studies include the … Read the full press release →

(IN BRIEF) South African clinical dietitian Lizl Veldsman has won the 2025 Harry M. Vars Award from ASPEN for her innovative ICU study supported by Fresenius Kabi. The study examined the impact of intravenous protein and in-bed cycling on muscle … Read the full press release →

(IN BRIEF) The Fresenius healthcare group is constructing a new facility, KabiLab D20, at Daimlerstrasse 20 on its Bad Homburg campus, set to cover 5,000 m². This modern laboratory and office building will feature state-of-the-art laboratories, 90 shared workstations, meeting … Read the full press release →

(IN BRIEF) Quest Diagnostics has agreed to acquire select assets from Fresenius Medical Care’s Spectra Laboratories, expanding its portfolio with dialysis-related laboratory and water testing services. This collaboration will enhance the care and efficiency of dialysis services across the U.S., … Read the full press release →

(IN BRIEF) A study by the Technical University of Munich (TUM), LMU Hospital Munich, and Helmholtz Munich found that while intermittent fasting benefits adult mice by improving insulin sensitivity, it harms beta cell development in adolescent mice, which could have … Read the full press release →

(IN BRIEF) Fresenius has signed a five-year global contract with Microsoft to enhance IT collaboration and security for its global workforce. Beginning in June 2025, the agreement will include tools such as Microsoft Defender, Microsoft 365, SharePoint, OneDrive, and Microsoft … Read the full press release →

(IN BRIEF) Fresenius Medical Care (FME) has been named the top company in Boston Consulting Group’s (BCG) Gender Diversity Index Germany for 2024, rising from 29th place the previous year. The recognition, featured in Manager Magazin, acknowledges FME’s progress in … Read the full press release →

(IN BRIEF) Fresenius Kabi is addressing the global threat of antimicrobial resistance (AMR), which causes millions of deaths annually, through sustainable manufacturing, improved antibiotic access, and promoting responsible use. During AMR Awareness Week, the company highlighted its commitment to reducing … Read the full press release →

(IN BRIEF) Fresenius Medical Care (FME), a global leader in renal healthcare, has earned a spot at #4 on Massachusetts’ Top 100 Women-Led Businesses list, compiled by The Women’s Edge and The Boston Globe. CEO Helen Giza’s leadership has been … Read the full press release →

(IN BRIEF) Fresenius Medical Care’s subsidiary, Xenios AG, has launched Xenios 2.0, a new system for extracorporeal life support (ECLS) that serves patients from neonates to adults. Approved under the new Medical Device Regulation (MDR), Xenios 2.0 offers advanced safety … Read the full press release →

(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This biosimilar is approved for the treatment of serious inflammatory diseases. … Read the full press release →

(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and intravenous formulations, will treat inflammatory conditions such as Crohn’s disease, plaque psoriasis, … Read the full press release →

(IN BRIEF) Wolters Kluwer has nominated Anjana Harve, currently the EVP and CIO at BJ’s Wholesale Club, for a position on its Supervisory Board, pending approval at an Extraordinary General Meeting (EGM) on October 28, 2024. Harve, a seasoned IT … Read the full press release →

(IN BRIEF) At the Annual General Meeting in Frankfurt am Main, shareholders of Fresenius SE & Co. KGaA overwhelmingly approved proposals from the General Partner and the Supervisory Board. Chairman of the Supervisory Board, Wolfgang Kirsch, commended Fresenius’ resilience amidst … Read the full press release →

(IN BRIEF) Fresenius Medical Care (FME), a global leader in renal disease solutions, unveils a pioneering Augmented Reality (AR) application aimed at revolutionizing training for Intensive Care Unit (ICU) nursing staff. The AR glasses, coupled with digital learning modules, offer … Read the full press release →

(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release →